Mohamad Javad Mirzaei-Parsa1,2, Mohammad Reza H Najafabadi3, Azadeh Haeri4, Masoumeh Zahmatkeshan5,6, Soltan Ahmad Ebrahimi7, Hamidreza Pazoki-Toroudi8, Moein Adel9,10. 1. Department of Medical Nanotechnology, Faculty of Allied Medical Sciences, Kerman University of Medical Sciences, Kerman, Iran. 2. Cell Therapy and Regenerative Medicine Comprehensive Center, Kerman University of Medical Sciences, Kerman, Iran. 3. Department of Medical Nanotechnology, School of Advanced Medical Technologies, Tehran University of Medical Sciences, Tehran, Iran. 4. Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 5. Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran. 6. Celullar and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran. 7. Department of Pharmacology, School of Medicine, Iran University of Medical Science, Tehran, Iran. 8. Physiology Department and Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran. 9. Deputy of Research and Technology, School of Medicine, Iran University of Medical Sciences, Hemat Highway Next to Milad Tower, Tehran, 1449614535, Iran. Adel.m@kar.iums.ac.ir. 10. Department of Medical Nanotechnology, School of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran. Adel.m@kar.iums.ac.ir.
Abstract
BACKGROUND: The aim of this study was to develop nonionic surfactant vesicles (niosomes) as a promising nanocarrier to enhance the anticancer activity of artemether. METHODS: The niosomes were prepared by thin-film hydration method containing a mixture of Span, Tween and cholesterol (Chol) in different molar ratios. All formulations were characterized in terms of size, entrapment efficiency (%EE), release profile and morphology. The optimized niosomal formulation (F7), artemether and phosphate buffered saline (PBS) were intratumorally administrated to mice as the nano-niosome group, the free drug group and the control group, respectively (n = 4 per group). Tumor volume was measured during the 12-day experiment, then mice were sacrificed to evaluate the necrosis, angiogenesis, and cell proliferation of tumor tissues by H&E, CD34 and Ki-67 immunostaining, respectively. RESULTS: Both artemether and nano-niosome groups could decrease angiogenesis and proliferation of tumor cells. However, in nano-niosome group superior tumor necrosis and smaller tumor volume were observed compared to both artemether and control groups. CONCLUSIONS: The niosomal formulation could be a promising carrier for breast cancer treatment.
BACKGROUND: The aim of this study was to develop nonionic surfactant vesicles (niosomes) as a promising nanocarrier to enhance the anticancer activity of artemether. METHODS: The niosomes were prepared by thin-film hydration method containing a mixture of Span, Tween and cholesterol (Chol) in different molar ratios. All formulations were characterized in terms of size, entrapment efficiency (%EE), release profile and morphology. The optimized niosomal formulation (F7), artemether and phosphate buffered saline (PBS) were intratumorally administrated to mice as the nano-niosome group, the free drug group and the control group, respectively (n = 4 per group). Tumor volume was measured during the 12-day experiment, then mice were sacrificed to evaluate the necrosis, angiogenesis, and cell proliferation of tumor tissues by H&E, CD34 and Ki-67 immunostaining, respectively. RESULTS: Both artemether and nano-niosome groups could decrease angiogenesis and proliferation of tumor cells. However, in nano-niosome group superior tumor necrosis and smaller tumor volume were observed compared to both artemether and control groups. CONCLUSIONS: The niosomal formulation could be a promising carrier for breast cancer treatment.
Entities:
Keywords:
Artemether; Breast cancer; Drug delivery system; Niosomes